MO10-2 Emerging molecular targets in AML: IDH1/2- and menin-related mutations (HM-SCREEN-JAPAN01)

FLT3 inhibitors are now available for acute myeloid leukemia (AML) in Japan and have modestly improved prognosis especially in patients who are relapsed/refractory or ineligible to standard therapy. FLT3 mutation, however, is detected in no more than 30% of patients with AML. IDH inhibitors were approved by FDA for patients with IDH1/IDH2-mutant AML. Recent studies have suggested that MLL-rearrangement, NPM1 mutation, and NUP98-fusion render leukemic potential through interaction with menin, which can be a novel therapy target.